Study #2024-1423
A phase 1/2 safety, dose-finding, and pharmacokinetics study of VNX-101 gene therapy in patients with relapsed or refractory CD19-positive hematologic malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
B-cell Acute Lymphoblastic Leukemia;Large B-cell Lymphoma;Chronic Lymphocytic Leukemia;Small Lymphocytic Lymphoma;Marginal Zone Lymphoma;Follicular Lymphoma;Mantle Cell Lymphoma;Diffuse Large B Cell Lymphoma;High-grade B-cell Lymphoma;Burkitt Lymphoma;Primary Mediastinal Large B-cell Lymphoma (PMBCL);Non Hodgkin Lymphoma;Mixed Phenotype Acute Leukemia
Study phase:
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.